[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100615022":3},{"organization":4,"armGroups":7,"interventions":24,"overallOfficials":35,"centralContacts":39,"locations":45,"responsibleParty":359,"collaborators":30,"id":361,"slug":362,"hasResults":363,"nctId":364,"briefTitle":365,"officialTitle":366,"acronym":367,"eligibilityCriteria":368,"healthyVolunteers":363,"sex":369,"minAge":370,"maxAge":371,"enrollmentInfo":372,"targetDuration":30,"studyType":375,"phases":376,"briefSummary":378,"conditions":379,"keywords":385,"overallStatus":48,"whyStopped":30,"lastUpdateSubmitDate":390,"lastUpdatePostDateStruct":391,"startDateStruct":394,"completionDateStruct":396,"leadSponsor":398,"locationsCount":399},{"fullName":5,"class":6},"Satellos Bioscience, Inc.","INDUSTRY",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"SAT-3247 60 mg","ACTIVE_COMPARATOR","SAT-3247 60 mg oral tablets administered daily for 12 weeks",[13],"Drug: SAT-3247",{"label":15,"type":10,"description":16,"interventionNames":17},"SAT-3247 120 mg","SAT-3247 120 mg oral tablets administered daily for 12 weeks; note the 120 mg dose will not be studied in the US and Canada",[13],{"label":19,"type":20,"description":21,"interventionNames":22},"placebo","PLACEBO_COMPARATOR","placebo oral tablets administered daily for 12 weeks",[23],"Drug: Placebo",[25,31],{"type":26,"name":27,"description":28,"armGroupLabels":29,"otherNames":30},"DRUG","SAT-3247","SAT-3247 is a selective AAK1 inhibitor for oral tablet administration which promotes functional rescue of asymmetric satellite cell division, resulting in the robust production of muscle progenitor cells, subsequent improvement in muscle regeneration, and enhanced muscle function.",[15,9],null,{"type":26,"name":32,"description":33,"armGroupLabels":34,"otherNames":30},"Placebo","matching placebo oral tablets",[19],[36],{"name":37,"affiliation":5,"role":38},"Satellos Chief Medical Officer","STUDY_DIRECTOR",[40],{"name":41,"role":42,"phone":43,"phoneExt":30,"email":44},"Satellos Medical Information","CONTACT","+1 647-660-1780","medicalinfo@satellos.com",[46,65,80,95,110,125,140,155,172,186,202,217,233,250,265,280,289,299,316,330,344],{"facility":47,"status":48,"city":49,"state":50,"zip":51,"country":52,"countryCode":53,"cosmosGeoPoint":54,"geoPoint":59,"contacts":60},"University of California Los Angeles","RECRUITING","Los Angeles","California","90095","United States","US",{"type":55,"coordinates":56},"Point",[57,58],-118.24368,34.05223,{"lat":58,"lon":57},[61],{"name":62,"role":42,"phone":63,"phoneExt":30,"email":64},"Denisse Velazquez","310-825-3264","Denissevelazquez@mednet.ucla.edu",{"facility":66,"status":48,"city":67,"state":68,"zip":69,"country":52,"countryCode":53,"cosmosGeoPoint":70,"geoPoint":74,"contacts":75},"Colorado Children's","Aurora","Colorado","80045",{"type":55,"coordinates":71},[72,73],-104.83192,39.72943,{"lat":73,"lon":72},[76],{"name":77,"role":42,"phone":78,"phoneExt":30,"email":79},"Nana Welnick","720-777-8608","Nanastasia.Welnick@childrenscolorado.org",{"facility":81,"status":48,"city":82,"state":83,"zip":84,"country":52,"countryCode":53,"cosmosGeoPoint":85,"geoPoint":89,"contacts":90},"Lurie Children's","Chicago","Illinois","60611",{"type":55,"coordinates":86},[87,88],-87.65005,41.85003,{"lat":88,"lon":87},[91],{"name":92,"role":42,"phone":93,"phoneExt":30,"email":94},"Alka Maheshwari","312-227-3813","amaheshwari@luriechildrens.org",{"facility":96,"status":48,"city":97,"state":98,"zip":99,"country":52,"countryCode":53,"cosmosGeoPoint":100,"geoPoint":104,"contacts":105},"UMass Memorial Medical Center","Worcester","Massachusetts","01655",{"type":55,"coordinates":101},[102,103],-71.80229,42.26259,{"lat":103,"lon":102},[106],{"name":107,"role":42,"phone":108,"phoneExt":30,"email":109},"Sarah Figueira","508-856-1604","Sarah.figueira@umassmed.edu",{"facility":111,"status":48,"city":112,"state":113,"zip":114,"country":52,"countryCode":53,"cosmosGeoPoint":115,"geoPoint":119,"contacts":120},"Washington University","St Louis","Missouri","63110",{"type":55,"coordinates":116},[117,118],-90.19789,38.62727,{"lat":118,"lon":117},[121],{"name":122,"role":42,"phone":123,"phoneExt":30,"email":124},"Natalie Goedeker","314-362-4919","NeuromusclePediatricResearch@wustl.edu",{"facility":126,"status":48,"city":127,"state":128,"zip":129,"country":52,"countryCode":53,"cosmosGeoPoint":130,"geoPoint":134,"contacts":135},"Nationwide Children's Hospital","Columbus","Ohio","43205",{"type":55,"coordinates":131},[132,133],-82.99879,39.96118,{"lat":133,"lon":132},[136],{"name":137,"role":42,"phone":138,"phoneExt":30,"email":139},"Jeremy Thompson","614-355-2923","jeremy.thompson@nationwidechildrens.org",{"facility":141,"status":48,"city":142,"state":143,"zip":144,"country":52,"countryCode":53,"cosmosGeoPoint":145,"geoPoint":149,"contacts":150},"Seattle Children's","Seattle","Washington","98105",{"type":55,"coordinates":146},[147,148],-122.33207,47.60621,{"lat":148,"lon":147},[151],{"name":152,"role":42,"phone":153,"phoneExt":30,"email":154},"Marissa Robertson","206-987-5457","marissa.robertson@seattlechildrens.org",{"facility":156,"status":157,"city":158,"state":159,"zip":160,"country":161,"countryCode":162,"cosmosGeoPoint":163,"geoPoint":167,"contacts":168},"Children's Hospital at Westmead","NOT_YET_RECRUITING","Westmead","New South Wales","2145","Australia","AU",{"type":55,"coordinates":164},[165,166],150.98768,-33.80383,{"lat":166,"lon":165},[169],{"name":170,"role":42,"phone":30,"phoneExt":30,"email":171},"Natasha Edirisinghege","Natasha.Edirisinghege@health.nsw.gov.au",{"facility":173,"status":48,"city":174,"state":175,"zip":176,"country":161,"countryCode":162,"cosmosGeoPoint":177,"geoPoint":181,"contacts":182},"Royal Children's Hospital Melbourne","Melbourne","Victoria","3052",{"type":55,"coordinates":178},[179,180],144.96332,-37.814,{"lat":180,"lon":179},[183],{"name":184,"role":42,"phone":30,"phoneExt":30,"email":185},"Ian Woodcock, MD","neurology.department@rch.org.au",{"facility":187,"status":48,"city":188,"state":188,"zip":189,"country":190,"countryCode":191,"cosmosGeoPoint":192,"geoPoint":196,"contacts":197},"Hôpital De La Citadelle (CHR)","Liège","4000","Belgium","BE",{"type":55,"coordinates":193},[194,195],5.56749,50.63373,{"lat":195,"lon":194},[198],{"name":199,"role":42,"phone":30,"phoneExt":200,"email":201},"Laurie Medard","+32043218222","laurie.medard@citadelle.be",{"facility":203,"status":48,"city":204,"state":205,"zip":206,"country":190,"countryCode":191,"cosmosGeoPoint":207,"geoPoint":211,"contacts":212},"UZ Gent","Ghent","Oost-Vlaanderen","9000",{"type":55,"coordinates":208},[209,210],3.71667,51.05,{"lat":210,"lon":209},[213],{"name":214,"role":42,"phone":215,"phoneExt":30,"email":216},"Julie Vancraeynest","+32 9 332 83 29","julie.vancraeynest@uzgent.be",{"facility":218,"status":48,"city":219,"state":220,"zip":221,"country":222,"countryCode":223,"cosmosGeoPoint":224,"geoPoint":228,"contacts":229},"Children's Hospital Eastern Ontario","Ottawa","Ontario","K1H8L1","Canada","CA",{"type":55,"coordinates":225},[226,227],-75.69812,45.41117,{"lat":227,"lon":226},[230],{"name":231,"role":42,"phone":30,"phoneExt":30,"email":232},"Emilie Hill-Smith","EHillSmith@cheo.on.ca",{"facility":234,"status":157,"city":235,"state":236,"zip":237,"country":238,"countryCode":239,"cosmosGeoPoint":240,"geoPoint":244,"contacts":245},"Klinika Neurologii Rozwojowej Uniwersyteckie","Gdansk","Pomeranian Voivodeship","80-952","Poland","PL",{"type":55,"coordinates":241},[242,243],18.64912,54.35227,{"lat":243,"lon":242},[246],{"name":247,"role":42,"phone":248,"phoneExt":30,"email":249},"Angelika Kamińska","48 58 349 23 31","ankaminska@uck.gda.pl",{"facility":251,"status":48,"city":252,"state":253,"zip":254,"country":238,"countryCode":239,"cosmosGeoPoint":255,"geoPoint":259,"contacts":260},"Instytut Centrum Zdrowia Matki Polki","Lodz","Łódź Voivodeship","93-338",{"type":55,"coordinates":256},[257,258],19.47395,51.77058,{"lat":258,"lon":257},[261],{"name":262,"role":42,"phone":263,"phoneExt":30,"email":264},"Joanna Wawrzynczak","48 42 271-16-11","joanna.wawrzynczak@iczmp.edu.pl",{"facility":266,"status":157,"city":267,"state":268,"zip":269,"country":268,"countryCode":270,"cosmosGeoPoint":271,"geoPoint":275,"contacts":276},"Clinic of Neurology and Psychiatry for Children and Youth","Belgrade","Serbia","11000","RS",{"type":55,"coordinates":272},[273,274],20.46513,44.80401,{"lat":274,"lon":273},[277],{"name":278,"role":42,"phone":30,"phoneExt":30,"email":279},"Ana Kosac","kosacana@gmail.com",{"facility":281,"status":157,"city":267,"state":268,"zip":269,"country":268,"countryCode":270,"cosmosGeoPoint":282,"geoPoint":284,"contacts":285},"University Children's Clinic Tirsova",{"type":55,"coordinates":283},[273,274],{"lat":274,"lon":273},[286],{"name":287,"role":42,"phone":30,"phoneExt":30,"email":288},"Raus Misela","michelleraus@gmail.com",{"facility":290,"status":157,"city":267,"state":268,"zip":291,"country":268,"countryCode":270,"cosmosGeoPoint":292,"geoPoint":294,"contacts":295},"Mother and Child Health Care Institute","11070",{"type":55,"coordinates":293},[273,274],{"lat":274,"lon":273},[296],{"name":297,"role":42,"phone":30,"phoneExt":30,"email":298},"Snezana Popovic","andjajockic@gmail.com",{"facility":300,"status":157,"city":301,"state":302,"zip":303,"country":304,"countryCode":305,"cosmosGeoPoint":306,"geoPoint":310,"contacts":311},"Hospital Universitario Donostia","Donostia \u002F San Sebastian","Basque Country","20014","Spain","ES",{"type":55,"coordinates":307},[308,309],-1.97499,43.31283,{"lat":309,"lon":308},[312],{"name":313,"role":42,"phone":314,"phoneExt":30,"email":315},"Josune Domínguez García","+34 688 693 705","JOSUNE.DOMINGUEZGARCIA@bio-gipuzkoa.eus",{"facility":317,"status":157,"city":318,"state":318,"zip":319,"country":304,"countryCode":305,"cosmosGeoPoint":320,"geoPoint":324,"contacts":325},"Hospital Universitario y Politécnico La Fe","Valencia","46026",{"type":55,"coordinates":321},[322,323],-0.37966,39.47391,{"lat":323,"lon":322},[326],{"name":327,"role":42,"phone":328,"phoneExt":30,"email":329},"Marta Campo Rodrigo","+34 630306333434654","marta_campo@iislafe.es",{"facility":331,"status":48,"city":332,"state":30,"zip":333,"country":304,"countryCode":305,"cosmosGeoPoint":334,"geoPoint":338,"contacts":339},"Hospital Infantil i Hospital de la Dona","Barcelona","08035",{"type":55,"coordinates":335},[336,337],2.15899,41.38879,{"lat":337,"lon":336},[340],{"name":341,"role":42,"phone":342,"phoneExt":30,"email":343},"Juan José Palmí Perales","+34 671 712 875","juan.palmi@vhir.org",{"facility":345,"status":157,"city":346,"state":347,"zip":348,"country":349,"countryCode":347,"cosmosGeoPoint":350,"geoPoint":354,"contacts":355},"Great Ormond Street","London","UK","WC1N 3JH","United Kingdom",{"type":55,"coordinates":351},[352,353],-0.12574,51.50853,{"lat":353,"lon":352},[356],{"name":357,"role":42,"phone":30,"phoneExt":30,"email":358},"Marta Zancolli","m.zancolli@ucl.ac.uk",{"type":360,"investigatorFullName":30,"investigatorTitle":30,"investigatorAffiliation":30,"oldNameTitle":30,"oldOrganization":30},"SPONSOR","100615022","phase-2-phase-2-study-of-sat-3247-in-pediatric-ambulatory-patients-100615022",false,"NCT07287189","Phase 2 Study of SAT-3247 in Pediatric Ambulatory Patients","A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Dose Comparison and Exploratory Efficacy Study of Orally Administered SAT-3247 in Ambulatory DMD Patients","BASECAMP","Key Inclusion Criteria:\n\n* Has a definitive diagnosis of DMD based on documented clinical findings and prior genetic testing with a confirmed mutation in the DMD gene.\n* Male DMD patients who are ambulatory and aged ≥ 7 to \\\u003C 10 years at the time of screening.\n* Stable dose of systemic glucocorticoids (i.e., prednisolone, deflazacort, or vamorolone) according to the standard of care for ≥ 3 months prior to the Screening Visit and for the duration of the trial. Patients who are not receiving glucocorticosteroids are also eligible if stopped ≥ 3 months prior to the Screening Visit.\n* Stable doses of prescription medicines including ACE inhibitors, β-blockers, and diuretics (excluding glucocorticosteroids) and over-the-counter medicines and\u002For herbal supplements for supportive care ≥ 1 month prior to the Screening Visit and for the duration of the trial.\n* Participants that have previously received delandistrogene moxeparvovec (brand name Elevidys) either in a prior clinical trial or in the commercial setting \\> 18 months prior to screening whose muscle function tests have stabilized or demonstrated decline ≥ 3 months prior to Screening, as determined by investigator and documented in chart notes, will be eligible.\n* Participants that have previously received an exon skipper \\> 6 months prior to Screening whose muscle function tests have stabilized or demonstrated decline ≥ 3 months prior to Screening, as determined by investigator and documented in chart notes, will be eligible.\n* Participants receiving a stable dose of givinostat (brand name Duvyzat) for at least 18 months or longer prior to the Screening Visit will be eligible. Participants unable to tolerate givinostat who discontinued treatment before 18 months are eligible to enroll if date of last dose is ≥ 30 days from the Screening date. Givinostat should not be discontinued, if tolerated, to meet study entry criteria.\n* Participants that have received prior treatment with an investigational gene therapy product (other than delandistrogene moxeparvovec) ≥ 24 months prior to the Screening Visit.\n* If participating in a physical therapy\u002Fstrength training regimen, must be stable for ≥ 2 months prior to the Screening Visit and for the duration of the trial.\n\nKey Exclusion Criteria:\n\n* Ambulatory patients expected to experience loss of ambulation within ≤ 12 months.\n* Participants for whom MRI or open muscle biopsy are contraindicated.\n* Evidence of significant hepatic dysfunction, defined as GLDH \\> 2X upper limit of normal (ULN) at the Screening Visit.\n* Impaired cardiac function defined as a left ventricular ejection fraction of \\\u003C 50% on screening cardiac assessments (echocardiogram or MRI) or evidence of symptomatic cardiomyopathy.\n* A forced vital capacity \\\u003C 60% predicted at the Screening Visit.\n* Ongoing participation in any other therapeutic clinical trial or follow-up study for a therapeutic intervention\n* Consumption of grapefruit juice or grapefruit containing products\n* Severe behavioural or cognitive problems that preclude participation in the study, in the opinion of the investigator.\n\nAdditional entry criteria will be reviewed with the clinical site investigator.","MALE","7 Years","9 Years",{"count":373,"type":374},51,"ESTIMATED","INTERVENTIONAL",[377],"PHASE2","Phase 2a trial of SAT-3247 in ambulatory DMD patients aged ≥ 7 and \\\u003C 10 years. The trial will study two doses of SAT-3247 in a randomized, double-blind, placebo-controlled weekday regimen for 12 weeks to determine the optimal dose, safety, tolerability, and preliminary efficacy.",[380,381,382,383,384],"Duchenne Muscular Dystrophy","Duchenne","DMD","Neuromuscular Diseases","Muscular Dystrophies",[386,387,388,389],"muscle regeneration","satellite cell","asymmetric division","dystrophin","2026-06-12",{"date":392,"type":393},"2026-06-16","ACTUAL",{"date":395,"type":393},"2025-12-08",{"date":397,"type":374},"2027-06-30",{"name":5,"class":6},21]